Glycorex Transplantation (GTAB B): enters into a distribution agreement in Brazil for Glycosorb® ABO

Glycorex Transplantation AB continues its market expansion strategy by entering into an agreement with Grupo VIDA for the distribution rights to Glycosorb® ABO in Brazil.

Grupo VIDA is a well-established medical technology distributor with 23 years of experience in importing and distributing high-quality products to the Brazilian healthcare market. The company has a solid background as a supplier to blood banks and bone marrow transplant centers, and is currently expanding its operations to include organ transplants.

"We are very proud to distribute Glycorex's high-technology products in Brazil. This collaboration is expected to shorten wait times for organ transplants and thereby contribute to saving more lives," says Adriano Pimenta, CEO of Grupo VIDA.
"Brazil, with a population of over 210 million, is an incredibly exciting market where more than 6,500 kidney transplants are performed annually across 177 centers nationwide. We are extremely pleased to initiate this collaboration with Grupo VIDA to increase the accessibility of Glycorex's life-saving technologies in the country," says Carl Magnus Schultz, CEO of Glycorex Transplantation.

For more information, please contact:
Carl-Magnus Schultz, CEO
Email: carl.schultz@glycorex.com, Phone: +46 46 286 52 30

Brief information about the company
Glycorex Transplantation AB (publ) is a global medical technology company headquartered in Sweden. The company has developed a unique medical technology (antigen-specific immunoadsorption) to specifically reduce blood group and autoantibodies in the blood.
The company’s focus areas are within transplantation, blood transfusion, and autoimmune diseases. The company has sales in over 30 countries, with Europe as its largest market. Sales take place through own sales channels and in cooperation with distributors in selected markets.
Product development and production takes place in the company’s own facility in Lund, Sweden.
Glycosorb® ABO is one of the company’s self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplantation by specifically reducing anti-A/B antibodies in the organ recipient’s plasma. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific publications have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 8,000 transplants in over 30 countries.
The company has also developed and CE-marked a medical device variant of Glycosorb® ABO that targets a different customer segment: transfusion clinics and blood centers. The product can help increase the availability of universal blood components and has been shown to be effective for the preparation of low-titer blood plasma, whole blood, and platelet concentrate.
The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.